ISDA

Deposition Date 2017-11-16

Release Date 2017-12-20

Last Version Date 2024-03-13

Entry Detail

PDB ID:

6BN6

Keywords:

TRANSCRIPTION/TRANSCRIPTION INHIBITOR

Title:

IDENTIFICATION OF BICYCLIC HEXAFLUOROISOPROPYL ALCOHOL SULFONAMIDES AS RORGT/RORC INVERSE AGONISTS

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.40 Å

R-Value Free:

0.22

R-Value Work:

0.20

R-Value Observed:

0.20

Space Group:

P 61

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Nuclear receptor ROR-gamma
Gene (Uniprot):RORC
Chain IDs:A, B
Chain Length:265
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:P51449 Pfam ID:PF00104

Ligand Molecules

SO4

XGH

Primary Citation

Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (ROR gamma /RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivity.

Gong, H, Weinstein, D.S, Lu, Z, Duan, J.J, Stachura, S, Haque, L, Karmakar, A, Hemagiri, H, Raut, D.K, Gupta, A.K, Khan, J, Camac, D, Sack, J.S, Pudzianowski, A, Wu, D.R, Yarde, M, Shen, D.R, Borowski, V, Xie, J.H, Sun, H, D'Arienzo, C, Dabros, M, Galella, M.A, Wang, F, Weigelt, C.A, Zhao, Q, Foster, W, Somerville, J.E, Salter-Cid, L.M, Barrish, J.C, Carter, P.H, Dhar, T.G.M.Show

Bioorg. Med. Chem. Lett. 28 85 93 (2018)

PMID: 29233651 DOI: 10.1016/j.bmcl.2017.12.006

Abstact

We disclose the optimization of a high throughput screening hit to yield benzothiazine and tetrahydroquinoline sulfonamides as potent RORγt inverse agonists. However, a majority of these compounds showed potent activity against pregnane X receptor (PXR) and modest activity against liver X receptor α (LXRα). Structure-based drug design (SBDD) led to the identification of benzothiazine and tetrahydroquinoline sulfonamide analogs which completely dialed out LXRα activity and were less potent at PXR. Pharmacodynamic (PD) data for compound 35 in an IL-23 induced IL-17 mouse model is discussed along with the implications of a high Ymax in the PXR assay for long term preclinical pharmacokinetic (PK) studies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures